Who Invented the Mammogram? A Look at Its History

No single person “invented” the mammogram in a flash of insight. The technology grew over decades, shaped by surgeons, radiologists, engineers, and public-health advocates across several countries. The earliest recognizable ancestor of the modern mammogram dates to 1913, when a German surgeon named Albert Salomon used X-rays to study breast tissue removed during mastectomies, producing the first systematic radiographic images of the breast. From that starting point, more than a century of refinement turned a crude laboratory technique into the most widely used breast-cancer screening tool in the world.

Albert Salomon and the First Breast X-Rays

Albert Salomon was a surgeon at the University of Berlin who had a straightforward idea: apply the still-new technology of X-ray imaging to surgically removed breast specimens and see what showed up. Working with roughly 3,000 mastectomy specimens, he was able to distinguish between different types of cancerous growths, spot tiny calcium deposits (microcalcifications), and even assess whether cancer had spread to nearby lymph nodes.¹ His work established the basic visual vocabulary that radiologists still rely on when reading mammograms today. Salomon was not imaging living patients, though. His X-rays were taken of tissue that had already been removed, which made his contribution more of a proof of concept than a clinical tool.

Several decades passed before anyone tried to apply X-ray imaging to breasts still attached to living women. In the 1930s and 1940s, a handful of radiologists in the United States and South America experimented with in-vivo breast imaging, but the equipment was clunky, radiation doses were high, and image quality was poor. The breast is a difficult organ to image because it is made up of soft tissues with only slight differences in density, so early general-purpose X-ray machines could not produce pictures detailed enough for reliable diagnosis.

Egan, Gros, and the Push Toward a Dedicated Technique

The real clinical breakthrough came in the late 1950s and 1960s. Robert Egan, a radiologist at the M.D. Anderson Hospital in Houston, developed a reproducible technique using high-resolution industrial film and specific exposure settings tailored to breast tissue. His method produced images sharp enough that other radiologists could learn it and get consistent results, which was the missing piece. Before Egan, breast X-rays were an artisanal skill that varied wildly between practitioners. After Egan, mammography could be taught, standardized, and scaled.

Around the same time, Charles Gros in Strasbourg, France, was working with an engineering firm to build the first X-ray machine designed exclusively for breast imaging. His device, called the Senographe, entered clinical use in the late 1960s. It featured a molybdenum anode X-ray tube that produced the specific wavelengths of radiation best suited for distinguishing breast tissues, along with a built-in compression mechanism. Compression, which squeezes the breast flat between two plates, was an unglamorous but critical innovation: it spreads the tissue out, reduces motion blur, and lowers the radiation dose needed to get a usable image. The Senographe became the template that essentially all dedicated mammography machines have followed since.

The Trial That Changed Screening Policy

Having a machine that could image breast tissue was one thing. Proving that using it routinely actually saved lives was another. That proof came from a landmark trial launched in December 1963 through the Health Insurance Plan (HIP) of Greater New York. Women between the ages of 40 and 64 were randomly assigned to either a screening group, which received mammography plus clinical breast exams once a year for four years, or a control group that received their usual care.² After 18 years of follow-up, the screened group had roughly 25 percent lower breast cancer mortality than the control group.²

The HIP trial was not perfect by modern standards. The mammographic equipment used in 1963 was far cruder than what came later, so the images likely missed cancers that newer machines would catch. Still, the trial demonstrated the core principle: catching breast cancer earlier through screening translated into fewer deaths. It became the foundation on which organized mammography screening programs were built, first in the United States and then worldwide.

From Trial to Mass Screening

Encouraged by the HIP results, the American Cancer Society and the National Cancer Institute jointly launched the Breast Cancer Detection Demonstration Project (BCDDP) in the 1970s. This was not a randomized trial but a massive demonstration program that offered five annual screening exams at 29 centers across the United States.³ Hundreds of thousands of women participated, and the BCDDP generated a wealth of data about how screening performed in real-world conditions. It also raised uncomfortable questions about radiation exposure, since the machines of that era delivered substantially higher doses than modern equipment.

The radiation concern was legitimate. Early mammography equipment exposed patients to doses that, by today’s standards, seem alarming. One alternative technology that briefly gained popularity was xeromammography, which used a selenium-coated plate instead of film to record the X-ray image. It produced distinctive blue-on-white images with excellent edge definition, making it easier to spot small lesions. However, xeromammography required roughly double the radiation dose of later screen-film systems, and the equipment was fussy and maintenance-heavy. It faded from use by the late 1980s as conventional screen-film mammography caught up in image quality while using less radiation.

Equipment Gets Better, Doses Go Down

Over the two decades following the BCDDP, the technology improved dramatically. Dedicated mammography X-ray tubes, better film-screen combinations, and improved developing chemistry all contributed. By the late 1980s, radiologists could obtain higher-quality mammograms at significantly lower radiation doses than what was possible just 20 years earlier.⁴ This progress was not driven by a single inventor but by steady collaboration between physicists, engineers, and radiologists, each refining one component at a time.

The improvements in image quality mattered for a practical reason beyond aesthetics. A sharper image with better contrast means a radiologist can detect smaller cancers and subtler signs of disease. As the machines got better, the argument for population-wide screening grew stronger because the technology was more likely to deliver on its promise of catching cancer early.

Regulation and Quality Standards

By the early 1990s, mammography had become widespread in the United States, but the quality of the exams varied enormously from one facility to the next. Some clinics used poorly maintained equipment, employed inadequately trained technologists, or had their images interpreted by physicians with minimal experience in breast imaging. Congress responded in 1992 by passing the Mammography Quality Standards Act (MQSA), which required the FDA to set and enforce uniform quality standards for every mammography facility in the country.⁵ The rules, which took effect in October 1994, covered equipment performance, technologist qualifications, radiologist credentials, and mandatory tracking of outcomes.⁶

The MQSA was a turning point. Facilities that could not meet the standards were forced to upgrade or shut down, and every clinic had to undergo regular inspections. The law essentially professionalized mammography in the United States, establishing it as a regulated medical service rather than something any radiology practice could offer at whatever quality level it chose. Similar quality frameworks were adopted in other countries over the following years.

The Screening Debate

Not everyone agreed that mass mammography screening was an unqualified success. The most contentious evidence came from the Canadian National Breast Screening Study (CNBSS), which enrolled nearly 90,000 women beginning in the 1980s and followed them for 25 years. Unlike the HIP trial, the CNBSS found no significant difference in breast cancer mortality between women who received annual mammography and those who received only physical breast exams. The 25-year hazard ratio was essentially 1.0, meaning the screened group fared no better than the controls.⁷

The Canadian study ignited fierce debate.⁸ Critics pointed out that the mammographic equipment used in the CNBSS was older technology and that the quality of the images may have been subpar. Defenders of the study argued that its randomization was sound and that the findings raised legitimate questions about whether mammography’s benefits had been overstated, particularly for women in their 40s. The reality is that both sides had a point: the HIP trial and later European trials generally found a mortality benefit, while the CNBSS did not. These conflicting results are a big part of why screening recommendations have shifted over the years and continue to vary between medical organizations.

The Digital Revolution

Film-based mammography dominated for decades, but the transition to digital began in earnest in the early 2000s. Digital mammography replaces film with electronic detectors that capture the X-ray image and display it on a computer screen. The images can be adjusted for brightness and contrast after the fact, stored electronically, and transmitted for remote reading. A large U.S. trial called the Digital Mammographic Imaging Screening Trial (DMIST) compared the two technologies head to head. For the overall population, digital and film performed similarly.⁹

Where digital clearly outshone film was in specific subgroups. Women under 50, women with dense breast tissue, and premenopausal women all had significantly better cancer detection with digital mammography.⁹ A closer look at the data found that the advantage was most pronounced among pre- or perimenopausal women under 50 who had dense breasts, where digital mammography’s sensitivity was more than double that of film.¹⁰ Dense breast tissue is common in younger women and has always been mammography’s Achilles’ heel, because dense tissue and tumors both appear white on the image, making cancers hard to spot. Digital imaging’s ability to manipulate contrast helped separate the two.

By the 2010s, film mammography had been almost entirely replaced by digital systems in high-income countries. The transition happened faster than many expected, driven in part by the practical advantages of electronic storage and transmission and in part by the improved performance in the dense-breast population that DMIST documented.

Tomosynthesis and the Third Dimension

The latest major hardware advance is digital breast tomosynthesis, often marketed as 3D mammography. Instead of taking a single flat image, the X-ray tube sweeps through a short arc around the compressed breast and captures a series of low-dose images from different angles. Software reconstructs these into thin slices, letting the radiologist scroll through the breast layer by layer rather than viewing everything superimposed in a single picture.

Clinical studies have shown that tomosynthesis catches more cancers, particularly invasive cancers, while also reducing the rate of false positives, meaning fewer women get called back for additional imaging that turns out to be nothing.¹¹ The false-positive problem has been one of mammography’s persistent headaches: callbacks cause anxiety, additional imaging, and sometimes biopsies that find no cancer. By reducing the tissue-overlap confusion that causes many false alarms, tomosynthesis addresses one of the most common patient complaints about the screening process.¹²

Artificial Intelligence Enters the Reading Room

The newest chapter in mammography’s history is being written by artificial intelligence. Deep learning algorithms trained on millions of mammographic images can now detect suspicious findings and flag them for the radiologist’s attention. Some of these algorithms approach the performance of experienced radiologists, particularly for cancer detection and for predicting a woman’s future breast-cancer risk based on the appearance of her mammographic images.¹³

AI is not replacing radiologists, at least not yet. The practical model in most clinics is a decision-support tool: the algorithm pre-screens the images, highlights areas of concern, and the radiologist makes the final call. This workflow has the potential to reduce reading errors caused by fatigue, since a radiologist reviewing hundreds of mammograms in a sitting can miss subtle findings that a tireless algorithm would not. Challenges remain around validation, regulatory approval, and the risk of algorithms performing differently across demographic groups, since an AI trained mostly on images from one population may be less accurate for another.¹⁴

What About Women With Very Dense Breasts?

Breast density has become one of the most talked-about issues in breast-cancer screening. Women with extremely dense breasts face a double disadvantage: their tissue density is itself a risk factor for breast cancer, and the overlapping dense tissue masks tumors on mammograms, reducing the exam’s sensitivity. For these women, supplemental screening with other imaging tools is increasingly recommended.

MRI is the most sensitive option, catching cancers that mammography and tomosynthesis miss, but it is expensive, time-consuming, and generates its own share of false positives. Ultrasound is cheaper and more accessible and does improve cancer detection rates in dense breasts, but it also increases false positives significantly.¹⁵ No supplemental modality is a free lunch. Each one trades off sensitivity against specificity and cost, and the best choice depends on the individual woman’s risk profile and circumstances.

The Compression Problem and Patient Experience

Ask anyone who has had a mammogram what they remember most, and the answer is often: the compression. Flattening the breast between two plates is essential for image quality and dose reduction, but it is also the most commonly cited reason women avoid or delay screening. Research confirms that pain and unpleasantness peak during the exam itself and that some residual discomfort lingers afterward. Anxiety going into the exam tends to amplify the pain experience.¹⁶

Efforts to improve the experience are underway. Patient-assisted compression devices, which let the woman control a handheld paddle to apply the compression herself, have shown promise. In one study, nearly three-quarters of women preferred the self-compression experience over their previous standard mammogram, and anxiety levels were significantly lower with the patient-controlled approach.¹⁷ Research has also shown that the staff’s demeanor and the degree to which the procedure is explained beforehand influence perceived pain as much as, or even more than, the physical compression itself.¹⁸ In other words, how the exam is delivered matters as much as the hardware.

A Technology With Many Inventors

If you were forced to pick one person to credit with “inventing” the mammogram, Albert Salomon’s 1913 X-ray studies of breast specimens would be the defensible choice for the earliest recognizable version. But that answer undersells how much the technology was reinvented along the way. Egan made it reproducible. Gros made it a dedicated machine. The HIP trial proved it saved lives. The MQSA forced it to meet quality standards. Digital detectors made it sharper for the patients who needed it most. Tomosynthesis gave it depth. AI is starting to give it a second pair of eyes. Each of these steps was, in a sense, a reinvention, and each involved different people in different countries solving different problems. Mammography is less a single invention than a century-long engineering and medical collaboration, still very much in progress.